← All Sangamo Therapeutics, INC filings

Sangamo Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

OTC.Pink
SGMO
Sangamo Therapeutics, INC
10-K: Sangamo Therapeutics Faces Going Concern Uncertainty Despite Collaboration Deals
Sangamo Therapeutics reports a net loss and expresses substantial doubt about its ability to continue as a going concern, even with recent collaboration agreements.
OTC.Pink
SGMO
Sangamo Therapeutics, INC
10-K: Sangamo Therapeutics Shifts Focus to Neurology, Announces Promising Preclinical Data
Sangamo Therapeutics is restructuring to focus on neurology, highlighting a novel AAV capsid for brain delivery and advancing preclinical programs.